CY1119245T1 - Φαρμακευτικη συνθεση καρβετοκινης - Google Patents

Φαρμακευτικη συνθεση καρβετοκινης

Info

Publication number
CY1119245T1
CY1119245T1 CY20171100893T CY171100893T CY1119245T1 CY 1119245 T1 CY1119245 T1 CY 1119245T1 CY 20171100893 T CY20171100893 T CY 20171100893T CY 171100893 T CY171100893 T CY 171100893T CY 1119245 T1 CY1119245 T1 CY 1119245T1
Authority
CY
Cyprus
Prior art keywords
carbetokin
pharmaceutical composition
relates
present
pharmaceutical compositions
Prior art date
Application number
CY20171100893T
Other languages
English (en)
Inventor
Anders Nilsson
Mattias Malm
Kazimierz Wisniewski
Britta Siekmann
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119245(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of CY1119245T1 publication Critical patent/CY1119245T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

Η παρούσα εφεύρεση αφορά σε φαρμακευτικές συνθέσεις που έχουν βελτιωμένη σταθερότητα.
CY20171100893T 2010-09-30 2017-08-23 Φαρμακευτικη συνθεση καρβετοκινης CY1119245T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10251690 2010-09-30
EP11776530.5A EP2621468B1 (en) 2010-09-30 2011-09-29 Pharmaceutical composition of carbetocin
PCT/IB2011/002394 WO2012042371A2 (en) 2010-09-30 2011-09-29 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
CY1119245T1 true CY1119245T1 (el) 2018-02-14

Family

ID=43478408

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100893T CY1119245T1 (el) 2010-09-30 2017-08-23 Φαρμακευτικη συνθεση καρβετοκινης
CY20221100079T CY1124924T1 (el) 2010-09-30 2022-02-01 Φαρμακευτικη συνθεση καρβετοκινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20221100079T CY1124924T1 (el) 2010-09-30 2022-02-01 Φαρμακευτικη συνθεση καρβετοκινης

Country Status (26)

Country Link
US (4) US9566311B2 (el)
EP (4) EP3246018B1 (el)
JP (2) JP6038797B2 (el)
KR (2) KR101919119B1 (el)
CN (4) CN104906032A (el)
AU (1) AU2011309762B2 (el)
BR (2) BR122021001123B1 (el)
CA (1) CA2812510A1 (el)
CY (2) CY1119245T1 (el)
DK (3) DK3222272T3 (el)
ES (3) ES2905561T3 (el)
HK (1) HK1246170A1 (el)
HR (2) HRP20211969T1 (el)
HU (3) HUE056835T2 (el)
IL (3) IL225238B (el)
JO (3) JO3400B1 (el)
LT (2) LT3222272T (el)
MX (1) MX352949B (el)
NZ (1) NZ609719A (el)
PL (3) PL3222272T3 (el)
PT (3) PT2621468T (el)
RS (2) RS56220B1 (el)
RU (2) RU2604690C2 (el)
SI (3) SI3246018T1 (el)
TW (6) TWI750934B (el)
WO (1) WO2012042371A2 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013260209A1 (en) * 2012-05-08 2014-11-20 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
JP6599447B2 (ja) * 2014-09-19 2019-10-30 フェリング ベスローテン フェンノートシャップ プラダー・ウィリー症候群を治療する方法
US10525099B2 (en) 2014-10-01 2020-01-07 Oxytone Bioscience B.V. Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance
CN107106640B (zh) * 2014-10-01 2021-06-15 奥克希托恩生物科学公司 含有分娩控制物质的口服崩解固体药物剂量单元
US9629894B2 (en) 2015-01-07 2017-04-25 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
CN107773531B (zh) * 2016-08-31 2021-05-04 成都倍特药业股份有限公司 一种马来酸麦角新碱注射液
CN108236601B (zh) * 2016-12-23 2020-04-17 深圳翰宇药业股份有限公司 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法
CA3070262A1 (en) * 2017-08-11 2019-02-14 Ferring B.V. Method of manufacturing a pharmaceutical composition
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
JP2021515005A (ja) 2018-03-01 2021-06-17 トライジェミナ， インコーポレイテッド 標識オキシトシンならびに製造および使用の方法
CN108721598B (zh) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 一种缩宫素原料的制备方法及其药物组合物和制剂
WO2020061414A1 (en) 2018-09-20 2020-03-26 Levo Therapeutics, Inc. Stable intranasal formulations of carbetocin
JP2022501440A (ja) 2018-09-20 2022-01-06 リーヴォ セラピューティクス， インコーポレイテッド カルベトシン医薬品およびその製造プロセス
EP3897571A1 (en) * 2018-12-21 2021-10-27 Arecor Limited Novel composition
WO2020137880A1 (ja) * 2018-12-27 2020-07-02 国立大学法人北海道大学 オキシトシン誘導体及びその使用
CN110308222A (zh) * 2019-07-17 2019-10-08 武汉赛沃医药科技有限公司 一种卡贝缩宫素原料药有关物质检测方法
CN110403904A (zh) * 2019-07-26 2019-11-05 翔宇药业股份有限公司 卡贝缩宫素注射液及其应用
CN110237230A (zh) * 2019-07-31 2019-09-17 南京康舟医药科技有限公司 一种卡贝缩宫素药物组合物及其制备方法
US20220313774A1 (en) 2019-11-04 2022-10-06 Ferring B.V. Intranasal administration of merotocin for improving lactation
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
WO2022200568A1 (en) 2021-03-26 2022-09-29 Ot4B Treatment of dysphagia
CN114191388B (zh) * 2021-12-27 2023-06-09 苏州天马医药集团天吉生物制药有限公司 一种卡贝缩宫素制剂的制备方法
CN114712483B (zh) * 2022-05-12 2023-09-29 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1109558A (zh) * 1994-11-07 1995-10-04 马文亮 装有压力表的双管气筒
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
PT916347E (pt) 1997-11-18 2003-07-31 Uni Pharma Kleon Tsetis A B E Solucoes farmaceuticas injectaveis contendo paracetamol e combinacoes de paracetamol com outras substancias activas
US6333313B1 (en) 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
US20070032410A1 (en) * 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
JP2001233787A (ja) 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
WO2004030524A2 (en) 2002-10-03 2004-04-15 Pr Pharmaceuticals Treatment of autism and similar disorders
EP2174663A1 (en) 2003-01-08 2010-04-14 Novartis Vaccines and Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (TFPI) or tissue factor pathway inhibitor variant
WO2004078147A2 (en) 2003-03-05 2004-09-16 Pr Pharmaceuticals Oxytocin controlled release formulations and methods of using same
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CN101677948A (zh) * 2007-06-07 2010-03-24 纳斯泰克制药公司 卡贝缩宫素鼻用制剂和治疗孤独症的方法
SI2178386T1 (sl) 2007-07-02 2011-01-31 Sime Darby Malaysia Berhad Sestavek maščobe za cvrtje
ES2319054B1 (es) 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
EP2626364A1 (en) * 2008-03-31 2013-08-14 Ferring BV Novel compounds
CN104013569A (zh) * 2008-10-15 2014-09-03 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用

Also Published As

Publication number Publication date
HRP20211969T1 (hr) 2022-03-18
JP2017048226A (ja) 2017-03-09
DK2621468T3 (en) 2017-09-11
TWI661834B (zh) 2019-06-11
LT3222272T (lt) 2021-12-27
CN107080832B (zh) 2021-05-07
HUE057187T2 (hu) 2022-04-28
AU2011309762B2 (en) 2014-07-17
HK1246170A1 (zh) 2018-09-07
CN107080832A (zh) 2017-08-22
JOP20180102B1 (ar) 2022-03-14
KR102102664B1 (ko) 2020-04-22
JOP20180103A1 (ar) 2019-01-30
EP3222272A1 (en) 2017-09-27
RU2016143751A3 (el) 2020-01-16
MX352949B (es) 2017-12-15
JP2013543492A (ja) 2013-12-05
PT3246018T (pt) 2022-01-13
IL245328A0 (en) 2016-06-30
SI3222272T1 (sl) 2022-01-31
TW201729797A (zh) 2017-09-01
EP2621468B1 (en) 2017-06-14
RS56220B1 (sr) 2017-11-30
WO2012042371A2 (en) 2012-04-05
DK3222272T3 (da) 2022-01-24
JP6038797B2 (ja) 2016-12-07
TW201605465A (zh) 2016-02-16
ES2637988T3 (es) 2017-10-18
IL225238B (en) 2018-07-31
US20230124105A1 (en) 2023-04-20
JOP20180102A1 (ar) 2019-01-30
JOP20180103B1 (ar) 2022-03-14
LT2621468T (lt) 2017-11-27
TWI750934B (zh) 2021-12-21
EP3246018A1 (en) 2017-11-22
US20170106043A1 (en) 2017-04-20
TW201605466A (zh) 2016-02-16
IL245326B (en) 2021-04-29
CN104906032A (zh) 2015-09-16
HRP20171256T1 (hr) 2017-10-20
BR122021001123B1 (pt) 2021-05-18
KR101919119B1 (ko) 2018-11-15
RU2013112666A (ru) 2014-11-10
DK3246018T3 (da) 2022-01-17
SI3246018T1 (sl) 2022-02-28
HUE034367T2 (en) 2018-02-28
CN103124554A (zh) 2013-05-29
TWI680773B (zh) 2020-01-01
US9566311B2 (en) 2017-02-14
IL225238A0 (en) 2013-06-27
CY1124924T1 (el) 2023-01-05
JO3400B1 (ar) 2019-10-20
RS62873B1 (sr) 2022-02-28
NZ609719A (en) 2014-07-25
BR112013007362A2 (pt) 2016-07-12
TWI746951B (zh) 2021-11-21
PL2621468T3 (pl) 2017-11-30
HUE056835T2 (hu) 2022-03-28
RU2016143751A (ru) 2018-12-18
KR20130136467A (ko) 2013-12-12
IL245328B (en) 2022-04-01
CA2812510A1 (en) 2012-04-05
IL245326A0 (en) 2016-06-30
EP3222272B1 (en) 2021-11-03
ES2902418T3 (es) 2022-03-28
MX2013003365A (es) 2013-07-29
EP3936117A1 (en) 2022-01-12
PT2621468T (pt) 2017-09-08
TW201940188A (zh) 2019-10-16
RU2604690C2 (ru) 2016-12-10
TW202112389A (zh) 2021-04-01
RU2737264C2 (ru) 2020-11-26
AU2011309762A1 (en) 2013-04-04
SI2621468T1 (sl) 2017-10-30
EP2621468A2 (en) 2013-08-07
US20170106044A1 (en) 2017-04-20
US20130210746A1 (en) 2013-08-15
KR20180123599A (ko) 2018-11-16
CN107412728A (zh) 2017-12-01
TWI650134B (zh) 2019-02-11
WO2012042371A3 (en) 2013-04-04
PL3222272T3 (pl) 2022-03-07
ES2905561T3 (es) 2022-04-11
TWI532507B (zh) 2016-05-11
PL3246018T3 (pl) 2022-05-02
BR112013007362B1 (pt) 2021-05-25
EP3246018B1 (en) 2021-11-03
PT3222272T (pt) 2022-01-27
TW201219051A (en) 2012-05-16
JP6250770B2 (ja) 2017-12-20

Similar Documents

Publication Publication Date Title
CY1119245T1 (el) Φαρμακευτικη συνθεση καρβετοκινης
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
EA201590887A1 (ru) Композиция
EA201590534A1 (ru) Новые бициклические производные
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
UY34414A (es) Composiciones hemostáticas
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
UA114087C2 (xx) Похідні піридину
UY33735A (es) Compuestos antivirales
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201300146A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ МОДУЛЯТОРА c-МЕТ
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
EA201490037A1 (ru) Антагонисты trpv4
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
UY34415A (es) Composiciones hemostáticas
EA201490846A1 (ru) Новые производные арилхинолина
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
CR20130501A (es) Derivados novedosos de cefalosporinas y composiciones farmacéuticas de estos
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
EA201290642A1 (ru) Соединения и способы
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения